Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 12 Nov 2026

Morepen Laboratories announced the launch of its first prescription generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs, for distribution in the U.S. market.

4 publishers have reported this development. Each act of reporting is below, cited.

The record

Morepen Laboratories announced the launch of its first prescription generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs, for distribution in the U.S. market.

Morepen Laboratories Limited announced the launch of its first prescription generic product, Desloratadine Tablets USP, 5 mg, for distribution in the U.S. market through its wholly owned U.S. arm, Morepen Bio Inc.

Morepen Laboratories announced the launch of its first prescription generic product in the US market, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs through its wholly owned US subsidiary, Morepen Bio Inc.

New Delhi: Morepen Laboratories announced the launch of anti-allergy medicine, desloratadine, in the US, marking the company’s entry in the world’d largest pharmaceutical market.

indiatimes.com10 Nov 2026

Morepen Laboratories has launched its prescription generic product Desloratadine in the United States market through its subsidiary, Morpen Bio. Inc.

indiatimes.com9 Nov 2026

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.